Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine for Chemoprotection in Patients Receiving DICEP Chemotherapy
NCT00003269Phase 2Completed
- Sponsor
- Scripps Health
- Start
- Feb 1998
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amifostine in chemotherapy-induced toxicity, sponsored by Scripps Health. Primary endpoint: Duration of neutropenia at 30 days. Started Feb 1998; status: completed.
02
Drugs
amifostine
03
Conditions
chemotherapy-induced toxicity
Beyond the preview
Go deeper on NCT00003269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003269.